Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Oncogene|June 15, 1995
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cellsR J Pietras, J Arboleda, D M Reese, et al.Oncogene|November 11, 1999
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cellsZ Aguilar, R W Akita, R S Finn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram, A Lipton, D F Hayes, et al.Oncogene|July 4, 2012
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5T M Ward, E Iorns, X Liu, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1B M Ryan, G E Konecny, S Kahlert, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensK L Blackwell, M D Pegram, E Tan-Chiu, et al.Breast Cancer Research and Treatment|December 6, 2011
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancerA J Montero, C M Diaz-Montero, Y E Deutsch, et al.Pageof 2